B. Braun CeGaT Surpasses Milestone of 1,000 Patient Samples Tested for Neuromuscular and 500 for Neurodegenerative Diseases; Will Introduce Comprehensive Genomic Testing Services for Neurodegenerative Diseases at the 2015 American Academy of Neurology (AAN

BETHLEHEM, Pa., April 15, 2015 (GLOBE NEWSWIRE) -- B. Braun CeGaT, a molecular diagnostics service provider with extensive experience in the area of neurological diseases (e.g. neuromuscular and neurodegenerative diseases, and epilepsy), will be exhibiting at the 67th Annual AAN Meeting held April 18-25 in Washington, DC. The Pennsylvania-based company will highlight a catalog of next generation sequencing-based tests that are designed to identify the specific molecular cause of various hereditary forms of neuromuscular and neurodegenerative diseases, epilepsy, migraines, and metabolic disorders in an individual patient.

In the latest update, B. Braun CeGaT offers 24 diagnostic panels covering over 360 genes for neurodegenerative diseases (NDD), 9 diagnostic panels covering over 260 genes for neuromuscular diseases (NMD) and 19 diagnostic panels covering over 400 total genes known to be associated with epilepsies and related disorders. The genes in these panels are sequenced at a very high coverage (800-1000x on average) to increase the probability of finding the causative variant in a patient’s DNA. Using these panels, B. Braun CeGaT has analyzed over 2,000 patients for epilepsy, over 1,000 for NMD and over 500 for NDD, giving the company advanced knowledge and expertise in the genetic causes of these diseases. B. Braun CeGaT offers complete testing in-house – from DNA isolation to issuing the medical report. To ensure the highest quality, we bring together our highly educated team of biologists, biochemists, and medical doctors specialized in human genetics.

At the AAN Annual Meeting, B. Braun CeGaT will also feature exome and trio-exome sequencing services for patients and families. Especially for patients with complex clinical cases, exome sequencing offers the chance to identify the genetic cause for the disease. Exome sequencing covers all protein-coding genes in the human genome (over 20,000). The ability to interrogate all genes simultaneously, combined with B. Braun CeGaT’s collective experience with diagnosing complex and rare diseases, can be particularly useful for finding undiscovered causative variants in cases where the cause cannot be readily identified.

Visit Booth #942 at the Walter E Washington Convention Center during the 2015 AAN Annual Meeting to learn more about the genetics of neurological diseases and B. Braun CeGaT’s diagnostic services.

About B. Braun CeGaT, LLC

B. Braun CeGaT, established in 2014, is the result of a partnership between B. Braun, a leading provider of medical products and services, and the Center for Genomics and Transcriptomics (CeGaT), a Germany-based molecular diagnostic laboratory. The company, which shares its headquarters with B. Braun in Bethlehem, Pennsylvania, was formed to serve the U.S. sequencing and diagnostics market by offering innovative molecular diagnostic services developed by CeGaT to U.S.-based healthcare providers.

CeGaT has created and pioneered diagnostic services for a wide range of disorders including cancer, epilepsy, neuromuscular disease, neurodegenerative disease, eye/vision-related disease, and more. CeGaT’s approach utilizes recent advancements in next generation sequencing technology, allowing for the simultaneous analysis of all genes associated with a particular disease. The information revealed by these tests can be used to identify the underlying cause of the disease in an individual patient and to help guide the course of treatment based on the patient’s unique genetic profile.

Dawn Brooke B. Braun CeGaT, LLC 824 Twelfth Avenue Bethlehem, PA 18018-3524 USA Email: dawn.brooke@bbrauncegat.com

Source:B. Braun CeGaT, LLC